These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25771228)

  • 1. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
    Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
    Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
    Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
    J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of suPAR with lifestyle and cardiometabolic risk factors.
    Botha S; Fourie CM; Schutte R; Kruger A; Schutte AE
    Eur J Clin Invest; 2014 Jul; 44(7):619-26. PubMed ID: 24810168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort.
    Frary CE; Blicher MK; Olesen TB; Stidsen JV; Greve SV; Vishram-Nielsen JK; Rasmussen SL; Olsen MH; Pareek M
    Eur J Prev Cardiol; 2020 Apr; 27(6):570-578. PubMed ID: 31718257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.
    Botha S; Fourie CM; Schutte R; Eugen-Olsen J; Schutte AE
    Hypertens Res; 2015 Jun; 38(6):439-44. PubMed ID: 25740290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
    Schutte AE; Myburgh A; Olsen MH; Eugen-Olsen J; Schutte R
    Thromb Res; 2012 Aug; 130(2):273-7. PubMed ID: 22113150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
    Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
    JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
    Rasmussen LJH; Petersen JEV; Eugen-Olsen J
    Front Immunol; 2021; 12():780641. PubMed ID: 34925360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular matrix biomarker, fibulin-1 and its association with soluble uPAR in a bi-ethnic South African population: the SAfrEIC study.
    du Plooy CS; Kruger R; Huisman HW; Rasmussen LM; Eugen-Olsen J; Schutte AE
    Heart Lung Circ; 2015 Mar; 24(3):298-305. PubMed ID: 25456503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
    Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
    Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study.
    Fourie CM; Van Rooyen JM; Kruger A; Olsen MH; Eugen-Olsen J; Schutte R; Schutte AE
    Inflammation; 2012 Feb; 35(1):221-9. PubMed ID: 21384094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
    Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
    Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. suPAR: A New Biomarker for Cardiovascular Disease?
    Hodges GW; Bang CN; Wachtell K; Eugen-Olsen J; Jeppesen JL
    Can J Cardiol; 2015 Oct; 31(10):1293-302. PubMed ID: 26118447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
    Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
    J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.